Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
192 studies found for:    Open Studies | "Cardiomyopathies"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
Condition: Cardiomyopathy
Intervention: Drug: Ranolazine
2 Recruiting Intracoronary Transplantation of Bone Marrow Derived Mononuclear Cells in Pediatric Cardiomyopathy
Condition: Cardiomyopathy
Intervention: Biological: Mono Nuclear Cell (MNC) transplantation
3 Recruiting Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
Condition: Cardiomyopathy
Intervention: Device: Three-lead CRT-D (Defibrillator)
4 Recruiting A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy
Condition: Dilated Cardiomyopathy
Intervention: Procedure: protein A immunoadsorption
5 Recruiting Cardiomyopathy Arrhythmia Risk Evaluation
Condition: Cardiomyopathy
Intervention:
6 Recruiting The Role of Emotional Stress in Patients With Stress-induced Cardiomyopathy
Condition: Takotsubo Cardiomyopathy
Intervention:
7 Not yet recruiting Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients
Condition: Cardiomyopathy
Intervention: Device: echocardiography
8 Not yet recruiting Bromocriptine in the Treatment of Peripartum Cardiomyopathy
Condition: Peripartum Cardiomyopathy
Interventions: Drug: Bromocriptine;   Other: Guideline-driven medical therapy (GDMT)
9 Recruiting Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy
Condition: Dilated Cardiomyopathy
Interventions: Device: protein A immunoadsorption;   Device: pseudo-immunoadsorption
10 Recruiting French Hypertrophic Cardiomyopathy Observatory
Condition: Hypertrophic Cardiomyopathy
Intervention:
11 Recruiting Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy
Condition: Cardiomyopathy
Intervention: Genetic: Identification of genetic polymorphisms
12 Recruiting Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients With Recent Onset Anthracycline-Associated Cardiomyopathy
Condition: Cardiomyopathy
Interventions: Biological: Human Mesenchymal Stem Cells (hMSCs);   Other: Standard of Care
13 Not yet recruiting The Chinese Hypertrophic Cardiomyopathy Study(CHCS)
Condition: Cardiomyopathy, Hypertrophic
Intervention:
14 Recruiting Brain fMRT In Takotsubo Cardiomyopathy
Condition: Takotsubo Cardiomyopathy
Intervention:
15 Recruiting Clinical and Genetic Examinations of Dilated Cardiomyopathy
Condition: Dilated Cardiomyopathy
Intervention:
16 Not yet recruiting Risk Stratification of Heart Failure in Cardiomyopathies.
Condition: Cardiomyopathy With Unknown Etiology
Interventions: Drug: etiologic treatment,anti-myocardial remodeling;   Drug: anti-myocardial remodeling;   Drug: anti-myocardial remodeling,anti-acute heart failure;   Drug: Etiological, anti-remodeling and symptom treatment
17 Recruiting Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Interventions: Procedure: Noncontrast echocardiography;   Procedure: Contrast Echocardiography;   Procedure: Cardiac magnetic resonance imaging
18 Recruiting Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy
Condition: Cardiomyopathy, Dilated
Intervention: Biological: Autologous stem cell therapy
19 Recruiting PHOspholamban RElated CArdiomyopathy STudy - Intervention
Condition: Phospholamban R14del Mutation-related Cardiomyopathy
Intervention: Drug: Eplerenone
20 Recruiting Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy
Condition: Primary Idiopathic Dilated Cardiomyopathy
Interventions: Other: bone marrow-derived MSCs injection;   Other: placebo intervention

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.